Injection Technique – BOTOXCosmetic.com

	Treatment Tour
	Before & After
	Injection Technique
	Dilution Table
	Prescribing Information

Clinical Information

Professional Organizations

Information for Consumers

Easy Administration
In order to reduce the complication of blepharoptosis:

Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow-depressor complexes¹
Medial corrugator injections should be placed at least 1 cm above the bony supraorbital ridge¹

BOTOX^® Cosmetic is to be reconstituted only with 0.9% sterile, non-preserved saline (100 Units in 2.5 mL saline) prior to intramuscular injection. The approved dose is 4 units per 0.1 mL at each of the 5 injection sites for a total dose of 20 units per 0.5 mL.

1. BOTOX^® Cosmetic [package insert]. Irvine, Calif: Allergan, Inc; 2002.

BOTOX^® Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in patients 18 to 65 years of age.

Important Safety Information

BOTOX^® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any ingredient in the formulation. There have been rare reports of adverse events involving the cardiovascular system. Serious and/or immediate hypersensitivity reactions have been reported rarely. These reactions include anaphylaxis, urticaria, soft-tissue edema, and dyspnea.

The most common adverse events following injection include blepharoptosis and nausea. Localized pain, infection, inflammation, tenderness, swelling, erythema and/or bleeding/bruising may be associated with the injection. Patients with neuromuscular disorders such as ALS, myasthenia gravis, or Lambert-Eaton syndrome may be at increased risk of serious adverse events.

Please see the additional safety information and full prescribing information.

Home | Prescribing Information | Privacy Policy | Contact Allergan | Site Map